Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy

Kala Y. Kamdar, Kevin R. Krull, Randa A. El-Zein, Pim Brouwers, Brian S. Potter, Lynnette L. Harris, Suzanne Holm, Zoann Dreyer, Fernando Scaglia, Carol J. Etzel, Melissa Bondy, M. Fatih Okcu

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Neurocognitive impairment occurs in 20-40% of childhood acute lymphoblastic leukemia (ALL) survivors, possibly mediated by folate depletion and homocysteine elevation following methotrexate treatment. We evaluated the relationship between folate pathway polymorphisms and neurocognitive impairment after childhood ALL chemotherapy. Procedure: Seventy-two childhood ALL survivors treated with chemotherapy alone underwent a neurocognitive battery consisting of: Trail Making Tests A (TMTA) and B (TMTB), Grooved Pegboard Test Dominant-Hand and Nondominant-Hand, Digit Span subtest, and Verbal Fluency Test. We performed genotyping for: 10-methylenetetrahydrofolate reductase (MTHFR 677C>T and MTHFR 1298A>C), serine hydroxymethyltransferase (SHMT 1420C>T), methionine synthase (MS 2756 A>G), methionine synthase reductase (MTRR 66A>G), and thymidylate synthase (TSER). Student's two sample t-test and analysis of covariance were used to compare test scores by genotype. Results: General impairment on the neurocognitive battery was related to MTHFR 1298A>C (P=0.03) and MS 2756A>G (P=0.05). Specifically, survivors with MTHFR 1298AC/CC genotypes scored, on average, 13 points lower on TMTB than those with MTHFR 1298AA genotype (P=0.001). The MS 2756AA genotype was associated with a 12.2 point lower mean TMTA score, compared to MS 2756 AG/GG genotypes (P=0.01). The TSER 2R/3R and 3R/3R genotypes were associated with an 11.4 point lower mean score on TMTB, compared to the TSER 2R/2R genotype (P=0.03). Survivors with ≥6 folate pathway risk alleles demonstrated a 9.5 point lower mean TMTA score (P=0.06) and 14.5 point lower TMTB score (P=0.002) than survivors with <6 risk alleles. Conclusions: Folate pathway polymorphisms are associated with deficits in attention and processing speed after childhood ALL therapy.

Original languageEnglish (US)
Pages (from-to)454-460
Number of pages7
JournalPediatric Blood and Cancer
Volume57
Issue number3
DOIs
StatePublished - Sep 1 2011

Fingerprint

Folic Acid
Leukemia
Genotype
Survivors
Trail Making Test
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutics
Hand
Glycine Hydroxymethyltransferase
Alleles
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
Drug Therapy
Methylenetetrahydrofolate Reductase (NADPH2)
Thymidylate Synthase
Homocysteine
Methotrexate
Students

Keywords

  • Folate
  • Leukemia
  • Neurocognitive
  • Survivor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Kamdar, K. Y., Krull, K. R., El-Zein, R. A., Brouwers, P., Potter, B. S., Harris, L. L., ... Okcu, M. F. (2011). Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy. Pediatric Blood and Cancer, 57(3), 454-460. https://doi.org/10.1002/pbc.23162

Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy. / Kamdar, Kala Y.; Krull, Kevin R.; El-Zein, Randa A.; Brouwers, Pim; Potter, Brian S.; Harris, Lynnette L.; Holm, Suzanne; Dreyer, Zoann; Scaglia, Fernando; Etzel, Carol J.; Bondy, Melissa; Okcu, M. Fatih.

In: Pediatric Blood and Cancer, Vol. 57, No. 3, 01.09.2011, p. 454-460.

Research output: Contribution to journalArticle

Kamdar, KY, Krull, KR, El-Zein, RA, Brouwers, P, Potter, BS, Harris, LL, Holm, S, Dreyer, Z, Scaglia, F, Etzel, CJ, Bondy, M & Okcu, MF 2011, 'Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy', Pediatric Blood and Cancer, vol. 57, no. 3, pp. 454-460. https://doi.org/10.1002/pbc.23162
Kamdar, Kala Y. ; Krull, Kevin R. ; El-Zein, Randa A. ; Brouwers, Pim ; Potter, Brian S. ; Harris, Lynnette L. ; Holm, Suzanne ; Dreyer, Zoann ; Scaglia, Fernando ; Etzel, Carol J. ; Bondy, Melissa ; Okcu, M. Fatih. / Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy. In: Pediatric Blood and Cancer. 2011 ; Vol. 57, No. 3. pp. 454-460.
@article{4a526c5008f74415805e85aef34bd415,
title = "Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy",
abstract = "Background: Neurocognitive impairment occurs in 20-40{\%} of childhood acute lymphoblastic leukemia (ALL) survivors, possibly mediated by folate depletion and homocysteine elevation following methotrexate treatment. We evaluated the relationship between folate pathway polymorphisms and neurocognitive impairment after childhood ALL chemotherapy. Procedure: Seventy-two childhood ALL survivors treated with chemotherapy alone underwent a neurocognitive battery consisting of: Trail Making Tests A (TMTA) and B (TMTB), Grooved Pegboard Test Dominant-Hand and Nondominant-Hand, Digit Span subtest, and Verbal Fluency Test. We performed genotyping for: 10-methylenetetrahydrofolate reductase (MTHFR 677C>T and MTHFR 1298A>C), serine hydroxymethyltransferase (SHMT 1420C>T), methionine synthase (MS 2756 A>G), methionine synthase reductase (MTRR 66A>G), and thymidylate synthase (TSER). Student's two sample t-test and analysis of covariance were used to compare test scores by genotype. Results: General impairment on the neurocognitive battery was related to MTHFR 1298A>C (P=0.03) and MS 2756A>G (P=0.05). Specifically, survivors with MTHFR 1298AC/CC genotypes scored, on average, 13 points lower on TMTB than those with MTHFR 1298AA genotype (P=0.001). The MS 2756AA genotype was associated with a 12.2 point lower mean TMTA score, compared to MS 2756 AG/GG genotypes (P=0.01). The TSER 2R/3R and 3R/3R genotypes were associated with an 11.4 point lower mean score on TMTB, compared to the TSER 2R/2R genotype (P=0.03). Survivors with ≥6 folate pathway risk alleles demonstrated a 9.5 point lower mean TMTA score (P=0.06) and 14.5 point lower TMTB score (P=0.002) than survivors with <6 risk alleles. Conclusions: Folate pathway polymorphisms are associated with deficits in attention and processing speed after childhood ALL therapy.",
keywords = "Folate, Leukemia, Neurocognitive, Survivor",
author = "Kamdar, {Kala Y.} and Krull, {Kevin R.} and El-Zein, {Randa A.} and Pim Brouwers and Potter, {Brian S.} and Harris, {Lynnette L.} and Suzanne Holm and Zoann Dreyer and Fernando Scaglia and Etzel, {Carol J.} and Melissa Bondy and Okcu, {M. Fatih}",
year = "2011",
month = "9",
day = "1",
doi = "10.1002/pbc.23162",
language = "English (US)",
volume = "57",
pages = "454--460",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy

AU - Kamdar, Kala Y.

AU - Krull, Kevin R.

AU - El-Zein, Randa A.

AU - Brouwers, Pim

AU - Potter, Brian S.

AU - Harris, Lynnette L.

AU - Holm, Suzanne

AU - Dreyer, Zoann

AU - Scaglia, Fernando

AU - Etzel, Carol J.

AU - Bondy, Melissa

AU - Okcu, M. Fatih

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background: Neurocognitive impairment occurs in 20-40% of childhood acute lymphoblastic leukemia (ALL) survivors, possibly mediated by folate depletion and homocysteine elevation following methotrexate treatment. We evaluated the relationship between folate pathway polymorphisms and neurocognitive impairment after childhood ALL chemotherapy. Procedure: Seventy-two childhood ALL survivors treated with chemotherapy alone underwent a neurocognitive battery consisting of: Trail Making Tests A (TMTA) and B (TMTB), Grooved Pegboard Test Dominant-Hand and Nondominant-Hand, Digit Span subtest, and Verbal Fluency Test. We performed genotyping for: 10-methylenetetrahydrofolate reductase (MTHFR 677C>T and MTHFR 1298A>C), serine hydroxymethyltransferase (SHMT 1420C>T), methionine synthase (MS 2756 A>G), methionine synthase reductase (MTRR 66A>G), and thymidylate synthase (TSER). Student's two sample t-test and analysis of covariance were used to compare test scores by genotype. Results: General impairment on the neurocognitive battery was related to MTHFR 1298A>C (P=0.03) and MS 2756A>G (P=0.05). Specifically, survivors with MTHFR 1298AC/CC genotypes scored, on average, 13 points lower on TMTB than those with MTHFR 1298AA genotype (P=0.001). The MS 2756AA genotype was associated with a 12.2 point lower mean TMTA score, compared to MS 2756 AG/GG genotypes (P=0.01). The TSER 2R/3R and 3R/3R genotypes were associated with an 11.4 point lower mean score on TMTB, compared to the TSER 2R/2R genotype (P=0.03). Survivors with ≥6 folate pathway risk alleles demonstrated a 9.5 point lower mean TMTA score (P=0.06) and 14.5 point lower TMTB score (P=0.002) than survivors with <6 risk alleles. Conclusions: Folate pathway polymorphisms are associated with deficits in attention and processing speed after childhood ALL therapy.

AB - Background: Neurocognitive impairment occurs in 20-40% of childhood acute lymphoblastic leukemia (ALL) survivors, possibly mediated by folate depletion and homocysteine elevation following methotrexate treatment. We evaluated the relationship between folate pathway polymorphisms and neurocognitive impairment after childhood ALL chemotherapy. Procedure: Seventy-two childhood ALL survivors treated with chemotherapy alone underwent a neurocognitive battery consisting of: Trail Making Tests A (TMTA) and B (TMTB), Grooved Pegboard Test Dominant-Hand and Nondominant-Hand, Digit Span subtest, and Verbal Fluency Test. We performed genotyping for: 10-methylenetetrahydrofolate reductase (MTHFR 677C>T and MTHFR 1298A>C), serine hydroxymethyltransferase (SHMT 1420C>T), methionine synthase (MS 2756 A>G), methionine synthase reductase (MTRR 66A>G), and thymidylate synthase (TSER). Student's two sample t-test and analysis of covariance were used to compare test scores by genotype. Results: General impairment on the neurocognitive battery was related to MTHFR 1298A>C (P=0.03) and MS 2756A>G (P=0.05). Specifically, survivors with MTHFR 1298AC/CC genotypes scored, on average, 13 points lower on TMTB than those with MTHFR 1298AA genotype (P=0.001). The MS 2756AA genotype was associated with a 12.2 point lower mean TMTA score, compared to MS 2756 AG/GG genotypes (P=0.01). The TSER 2R/3R and 3R/3R genotypes were associated with an 11.4 point lower mean score on TMTB, compared to the TSER 2R/2R genotype (P=0.03). Survivors with ≥6 folate pathway risk alleles demonstrated a 9.5 point lower mean TMTA score (P=0.06) and 14.5 point lower TMTB score (P=0.002) than survivors with <6 risk alleles. Conclusions: Folate pathway polymorphisms are associated with deficits in attention and processing speed after childhood ALL therapy.

KW - Folate

KW - Leukemia

KW - Neurocognitive

KW - Survivor

UR - http://www.scopus.com/inward/record.url?scp=79960174296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960174296&partnerID=8YFLogxK

U2 - 10.1002/pbc.23162

DO - 10.1002/pbc.23162

M3 - Article

C2 - 21618410

AN - SCOPUS:79960174296

VL - 57

SP - 454

EP - 460

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -